Trials / Completed
CompletedNCT04782505
Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers
A Open-label, Single-dose, Phase 1 Study to Compare and Evaluate the Safety and Pharmacokinetics According to the Dose of Camostat Mesylate in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Safety and pharmacokinetics evaluation study according to the dose of camostat mesylate in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWJ1248 | Camostat mesylate Tablet from Daewoong |
Timeline
- Start date
- 2021-03-12
- Primary completion
- 2021-03-16
- Completion
- 2021-06-28
- First posted
- 2021-03-04
- Last updated
- 2022-12-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04782505. Inclusion in this directory is not an endorsement.